What diseases are treated with nebulized recombinant human interferon α2b injection?
Nov 25, 2025
Source: Cainiu Health
Dr. Ren Yi
Introduction
Diseases commonly treated with nebulized recombinant human interferon α2b injection generally include viral pneumonia, viral bronchitis, herpangina, hand-foot-and-mouth disease, and chickenpox. Through nebulized inhalation, this drug acts directly on the respiratory mucosa, inhibiting replication of pathogens such as influenza virus and respiratory syncytial virus, reducing pulmonary inflammatory responses, and alleviating symptoms such as fever, cough, and shortness of breath.
Ne雾化 therapy with recombinant human interferon α2b injection is generally used to treat diseases such as viral pneumonia, viral bronchitis, herpangina, hand-foot-and-mouth disease, and chickenpox. A detailed analysis is as follows:
1. Viral Pneumonia: When administered via nebulization, this medication acts directly on the respiratory mucosa, inhibiting replication of pathogens such as influenza virus and respiratory syncytial virus, reducing pulmonary inflammatory response, alleviating symptoms like fever, cough, and shortness of breath, and promoting absorption of lung inflammation.
2. Viral Bronchitis: For bronchitis caused by viral infection, nebulized administration achieves high local drug concentration in the bronchial mucosa, preventing viral spread, reducing congestion and edema of the bronchial mucosa, improving airway narrowing, and relieving symptoms such as wheezing and sputum production.
3. Herpangina: After nebulization, the drug can act on herpetic lesions in the pharynx, inhibit replication of pathogenic viruses such as Coxsackievirus, reduce pharyngeal inflammation and pain, promote healing of ulcers, and decrease feeding difficulties caused by pain.
4. Hand-Foot-and-Mouth Disease: In patients with hand-foot-and-mouth disease who also have respiratory tract infection symptoms, nebulized use of this drug can target respiratory viral infections, relieve cough and sore throat, assist in controlling systemic viral progression, and reduce the risk of complications.
5. Chickenpox: In patients with chickenpox who develop respiratory symptoms such as cough or sore throat, nebulized administration can inhibit replication of varicella-zoster virus in the respiratory mucosa, reduce respiratory inflammation, and prevent progression to severe complications such as pneumonia.
Dosage and duration of nebulized therapy with this medication must strictly follow medical instructions; self-adjustment of dosage or treatment course is not recommended. If adverse reactions such as choking cough or worsening shortness of breath occur during nebulization, administration should be stopped immediately and the physician informed.
